Trials / Unknown
UnknownNCT04395612
Niraparib Combined With Brivanib or Toripalimab in Patients With Cervical Cancer
A Clinical Proof-of-concept Study Evaluating Efficacy and Safety of ZL-2306 (Niraparib) Combined With Brivanib or Toripalimab in Patients With Metastatic, Recurrent, and Persistent Cervical Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 38 (estimated)
- Sponsor
- Chongqing University Cancer Hospital · Academic / Other
- Sex
- Female
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
A Clinical Proof-of-concept Study Evaluating Efficacy and Safety of ZL-2306 (Niraparib) Combined With Brivanib or Toripalimab in Patients With Metastatic, Recurrent, and Persistent Cervical Cancer
Detailed description
A prospective, open-ended, single-arm, phase II clinical study.Patients are with metastatic, recurrent, persistent cervical cancer (squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma) To observe the efficacy and safety of ZL-2306 (Niraparib) combined with Brivanib or Toripalimab in patients with metastatic, recurrent and persistent cervical cancer, and to explore the biomarkers of effectiveness.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | niraparib combined with brivanib | Drug：Niraparib will be administered as a dose of 200 mg orally every day. Drug：Brivanib will be administered as a dose of 400mg orally every day. |
| DRUG | niraparib combined with toripalimab | Drug：Niraparib will be administered as a dose of 200 mg orally every day. Drug：Toripalimab will be administered as a dose of 240mg Intravenously every 21days. |
Timeline
- Start date
- 2020-05-08
- Primary completion
- 2022-04-01
- Completion
- 2022-07-01
- First posted
- 2020-05-20
- Last updated
- 2021-05-21
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04395612. Inclusion in this directory is not an endorsement.